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Deregulated energetics is a hallmark of malignancy, but metabolic heterogeneity among individual tumors
is unknown. A study by Caro et al. in this issue of Cancer Cell demonstrates that a subset of lymphomas
is defined by reliance on mitochondrial energy generation and is selectively killed when this pathway is
impaired.Altered metabolism was among the first
cancer biomarkers (Koppenol et al.,
2011). By 1925, Otto Warburg had ob-
served that tumors rapidly took up
glucose and converted it to lactic acid,
which was released into the milieu. This
was a departure from the other organs
he studied, which imported less glucose,
oxidized a higher fraction of it to carbon
dioxide, and secreted much less lactate.
This remarkable phenotype, called the
‘‘Warburg effect,’’ provides the rationale
for two modern imaging technologies in
cancer diagnosis: 18fluoro-2-deoxyglu-
cose positron emission tomography
(FDG-PET) to identify tumors by rapid
glucose import and 1H magnetic reso-
nance spectroscopy to identify areas of
elevated lactate. Over the last two
decades, the Warburg effect has been
mechanistically tied to the molecular
basis of transformation, as tumor-pro-
moting mutations in many different onco-
genes and tumor suppressors have been
demonstrated to stimulate glycolysis
(Ward and Thompson, 2012).
Cells have two ways to produce adeno-
sine triphosphate (ATP) for energy: gly-
colysis and oxidative phosphorylation
(OxPhos) (Figure 1). In glycolysis, glucose
is converted to pyruvate, generating
NADH from NAD+ and ATP from ADP. If
the pyruvate is reduced to lactate, NAD+
is regenerated and glycolysis continues.
Although glycolysis is rapid, it is deemed
inefficient because most of the energy
that could be generated from glucose
is lost when the cell secretes lactate.
In contrast, OxPhos is highly efficient.
When substrates like pyruvate are
oxidized in the mitochondria, reducing
equivalents are delivered to the elec-
tron transport chain, creating a proton
gradient coupled to ATP synthesis(Figure 1). This system yields nearly 20
times as many ATP molecules per
glucose as the Warburg effect. Other
oxidizable substrates, like fatty acids,
produce an even higher energy yield.
Warburg considered tumor glycolysis
to be a metabolic anomaly, famously
postulating that it was the consequence
of irreversible defects in respiration (i.e.,
OxPhos) which were the root cause of
cancer (Warburg, 1956). This model has
been disproven as a general principle,
because most cancer cells do not have
static defects in their respiratory
machinery, and more pointedly, because
nonmalignant cells also display the
Warburg effect if stimulated to grow
(Wang et al., 1978). Nevertheless, the
concept that glycolysis is a universal
feature of aggressive tumor growth, and
that OxPhos is counter-productive to
tumorigenesis still pervades the literature.
It was therefore surprising when a bio-
informatics study on diffuse large B cell
lymphoma (DLBCL) revealed that some
30% of these tumors belonged to a
subset defined by high expression of
genes involved in OxPhos (Monti et al.,
2005). DLBCL is the most common non-
Hodgkin’s lymphoma in Western popu-
lations and is characterized by rapid
growth. Several attempts have been
made to classify DLBCL by molecular
typing, particularly through shared
patterns of gene expression. One such
approach revealed three major DLBCL
subtypes: the OxPhos subset; the B cell
receptor (BCR) subset, characterized by
expression of genes involved in B cell
receptor signaling; and the host response
(HR) subset, expressing markers of infil-
trating inflammatory cells (Monti et al.,
2005). Now, a study in this issue of
Cancer Cell (Caro et al., 2012) examinesCancer Cell 22the metabolic phenotypes of these sub-
types and found that OxPhos cell lines
and primary biopsies contained elevated
expression of many mitochondrial pro-
teins. OxPhos cells displayed enhanced
glucose oxidation relative to lactate
formation, better defenses against oxida-
tive stress, and a robust ability to oxidize
fatty acids in the mitochondria. Providing
exogenous fatty acids stimulated survival
and growth in OxPhos cells, but not in
cells from other subtypes. Overall, cells
from OxPhos tumors generated a higher
fraction of their ATP in the mitochondria,
and this activity was required for cellular
fitness.
Importantly, inhibition of mitochondrial
metabolism selectively killed OxPhos
cells. The nuclear receptor peroxisome
proliferator-activated receptor gamma
(PPARg), which regulates the expression
of many genes encoding mitochondrial
proteins, was overexpressed in OxPhos
DLBCLs. PPARg antagonists suppressed
fatty acid oxidation and killed OxPhos
cells in culture. Inhibitors of fatty acid
oxidation had the same effect, as did
silencing of an enzyme required to
synthesize the antioxidant glutathione.
None of these treatments affected non-
OxPhos cells.
The work illustrates several key prin-
ciples in cancer metabolism. First,
it demonstrates significant metabolic
heterogeneity among tumors of the
same type. This point should be empha-
sized, because it tempers the paradigm
that tumors are monolithic in their prefer-
ence for glycolytic energy production.
Second, metabolic heterogeneity is pro-
grammed, and it persists when cells are
adapted to culture. This argues strongly
against the concept that the glycolytic
phenotype of most cancer cell lines is, October 16, 2012 ª2012 Elsevier Inc. 423
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Figure 1. Variable Reliance on Oxidative
Phosphorylation in DLBCL
Cells produce ATP from glycolysis (blue pathway) and oxida-
tive phosphorylation (OxPhos, green). Cancer cell lines vary
according to what fraction of their total ATP comes from
each pathway, as shown on the spectrum at the bottom. A
subset of DLBCL tumors was defined by high expression of
genes related to OxPhos. These cells produced most of their
ATP from OxPhos and required this pathway for survival and
growth. Non-OxPhos cells, which did not share this gene
expression signature, produced a higher fraction of their ATP
from glycolysis, and were resistant to OxPhos inhibition.
Abbreviation: TCA, tricarboxylic.
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culture conditions. Even the
suppression of OxPhos in other
DLBCL subtypes was programmed,
because these cells could be stimu-
lated to activate fatty acid oxidation
simply by silencing Syk, a kinase in
BCR signaling. Third, high rates of
OxPhos can support growth in
cancer cell lines. This may also be
true in vivo. Although a complete
clinical description of the OxPhos
DLBCL is lacking, patients with
these tumors do not appear to
survive any longer than those with
other types (Monti et al., 2005). The
aggressive course of DLBCL as a
whole suggests that a preference
for OxPhos does not prevent rapid
cell growth in the large subset
of tumors using that metabolic plat-
form. Thus, metabolic programming
to use the mitochondria rather than
glycolysis as themajor site of energy
formation is an effective strategy for
cancer cell growth.
The findings also emphasize that
cancer cells, like normal cells, use
multiple pathways concurrently to
produce energy (Figure 1). The
vast majority of cancer cells use
both glycolysis and OxPhos
together, although the balance
between the two varies widely (Zu
and Guppy, 2004). DLBCL cells
are no exception. Despite their
ability to oxidize pyruvate and
fatty acids in the mitochondria,
OxPhos cells still consumed glu-
cose and secreted a modest
amount of lactate. Conversely, the
non-OxPhos cells still producedhalf of their ATP in the mitochondria (Fig-
ure 1). Along these lines, a large majority
of DLBCL tumors are readily detected
by FDG-PET, and this likely includes
OxPhos tumors. Thus, avid uptake of
glucose analogs may occur even when
the mitochondria are fully active. Another
recent study on metabolic flux in glio-
blastoma reached this same conclusion
(Maher et al., 2012). Besides ATP, mito-
chondria produce biosynthetic precur-
sors, reactive oxygen species, and other424 Cancer Cell 22, October 16, 2012 ª2012factors that stimulate cell growth and
may contribute to tumorigenesis (Wein-
berg et al., 2010).
It remains to be seen whether the
OxPhos phenotype is driven by tumori-
genic mutations or other features of
DLBCL biology, and whether it bestows
some context-specific advantage to this
subset. Regardless of the mechanism, it
is encouraging that molecular phenotyp-
ing led to the discovery of metabolic
vulnerabilities in DLBCL. In a sense, theElsevier Inc.new work fortifies Warburg’s histor-
ical claim that metabolism is an
‘‘actionable’’ biomarker (even if
he would have been surprised by
these particular results). PPARg
antagonism may provide a starting
point for targeting OxPhos tumors,
and it would also be interesting
to determine whether OxPhos pre-
dicts sensitivity to therapies
currently in use for cancer. New
approaches to image tumor meta-
bolism noninvasively (Kurhanewicz
et al., 2011) may soon make it
possible to stratify patients to
therapeutic regimens solely by
probing metabolism in vivo.REFERENCES
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